⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25340342 | 0.97 | ALOX15 (0.33) | — | |
| SCHEMBL6570285 | 0.86 | — | — | |
| Fumaric Acid SCHEMBL4345931 | 0.85 | TSHR (0.41) | — | |
| SCHEMBL17652004 | 0.84 | LMNA (0.39) | — | |
| SCHEMBL2170581 | 0.84 | LMNA (0.39) | — | |
| SCHEMBL30700115 | 0.80 | GAA (0.36) | — | |
| SCHEMBL6344934 | 0.80 | GAA (0.36) | — | |
| SCHEMBL30700093 | 0.80 | GAA (0.36) | — | |
| SCHEMBL7700780 | 0.80 | — | — | |
| SCHEMBL3848183 | 0.78 | SCN5A (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116875389-A | Leavening agent and preparation method, application and application method thereof | 深圳市贝加电子材料有限公司 | 2023-10-13 | — | — | CN | claimed |
| EP-2673242-B1 | HYDROPHOBING DISPERSION GEL, METHOD FOR PRODUCING SAME, AND USE THEREOF FOR THE DEEP HYDROPHOBING OF MINERAL MATERIALS | IONYS AG (DE) | 2015-05-06 | — | — | EP | claimed |
| US-7566803-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-07-28 | — | — | US | claimed |
| US-20090018058-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (US) | 2009-01-15 | — | — | US | claimed |
| EP-0950657-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors | LILLY CO ELI (US) | 2004-07-14 | — | — | EP | claimed |
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | claimed |
| EP-1156050-B1 | Substituted tricyclics useful in sPLA2 induced diseases | LILLY CO ELI (US) | 2004-02-18 | — | — | EP | claimed |
| EP-1140943-B1 | SUBSTITUTED PYRROLOINDOLES | LILLY CO ELI (US) | 2003-08-13 | — | — | EP | claimed |
| JP-10204348-A | — | — | None | — | — | JP | disclosed |
| EP-4651872-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250043165-A1 | LOW-TEMPERATURE CURING COATING COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| US-20240294780-A1 | ELECTRODEPOSITABLE COATING COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2024155601-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | SEPTERNA, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20240197661-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-06-20 | — | — | US | disclosed |
| WO-1999054300-A1 | PROCESS FOR PREPARING 4-SUBSTITUTED-1H-INDOLE-3-GLYOXAMIDES | ELI LILLY AND COMPANY (US) | 1999-10-28 | — | — | WO | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0950661-A1 | Substituted tricyclics useful in sPLA2 induced diseases | ELI LILLY AND COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0950657-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |
| JP-H10204348-A | INK-JET INK COMPOSITION | XEROX CORP | 1998-08-04 | — | — | JP | disclosed |
| CN-1097740-A | 3-acyl group-2-oxindole-1-benzamide type prodrugs of antiinflammatory | PFIZER (US) | 1995-01-25 | — | — | CN | disclosed |